Iowa City, IANCT04422912Now EnrollingIRB Ready

Pemphigus Vulgaris Clinical Trial in Iowa City, IA

Access cutting-edge pemphigus vulgaris treatment through this clinical trial at a research site in Iowa City. Study-provided care at no cost to qualified participants.

Sponsored by Cabaletta Bio

Quick Self-Assessment

See if you qualify for this Iowa City location

Preparing your pre-screening questions…

Expert Care in Iowa City

Access pemphigus vulgaris specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related pemphigus vulgaris treatment provided free

Apply for This Iowa City Location

Check if you qualify for this pemphigus vulgaris clinical trial in Iowa City, IA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Iowa City

    Convenient for IA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Iowa City site if eligible
  4. 4Begin participation

About This Pemphigus Vulgaris Study in Iowa City

A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \[DSG3-CAART\] or CD19-specific Chimeric Antigen Receptor T cells \[CABA-201\]) in subjects with active, pemphigus vulgaris

Sponsor: Cabaletta Bio

Who Can Participate

Inclusion Criteria

for DSG3-CAART: Closed to enrollment
Confirmed diagnosis of mPV by prior or screening biopsy and prior positive anti- DSG3 antibody ELISA
mPV inadequately managed by at least one standard immunosuppressive therapies
Active mPV at screening
Anti-DSG3 antibody ELISA positive at screening Inclusion Criteria for CABA-201 sub-study: Open to enrollment
Confirmed diagnosis of PV by prior or screening biopsy and prior positive DSG3 ELISA, IIF, and/or DIF
PV inadequately managed by at least one standard immunosuppressive therapy
Active PV at screening
DSG3 ELISA positive at screening

Exclusion Criteria

Active cutaneous lesions associated with PV that indicates mucocutaneous rather than mucosal-dominant disease
Rituximab in last 12 months unless PV symptoms have recently worsened or anti-DSG3 antibody titers have recently increased
Prednisone \> 0.25mg/kg/day
Other autoimmune disorder requiring immunosuppressive therapies
Investigational treatment in last 3 months Exclusion Criteria for CABA-201 sub-study
Have paraneoplastic pemphigus or active malignancy (not including non-melanoma skin cancer) or malignancy diagnosed within the previous 5 years
Have received rituximab or other anti-CD20 or anti-CD19 therapies in last 12 months unless anti-DSG3 antibody titers have recently increased or PV symptoms have recently worsened
Prednisone \> 0.25mg/kg/day
Other autoimmune disorder requiring immunosuppressive therapies
Treatment with any investigational agent within 4 weeks or 5 half-lives, whichever is longer.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Iowa City?

Yes, this clinical trial (NCT04422912) has an active research site in Iowa City, IA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pemphigus Vulgaris Treatment Options in Iowa City, IA

If you're searching for pemphigus vulgaris treatment options in Iowa City, IA, this clinical trial (NCT04422912) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Iowa City research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pemphigus vulgaris specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pemphigus vulgaris clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in Iowa City, IA

See all pulmonary embolism clinical trials recruiting in Iowa City — not just this study.

Browse Pulmonary Embolism Trials in Iowa City →

Browse More Trials by Condition

Pulmonary Embolism TrialsPulmonary Hypertension TrialsPemphigus TrialsGeographic Atrophy TrialsAll Conditions →

Ready to Join in Iowa City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Iowa City, IA